Bioinformatic analysis linking genomic defects to chemosensitivity and mechanism of action
Fig 5
Panel A: SOMDTP projections for FDA approved compounds for the primary CellMiner assigned MOAs.
Projections include the top 10th percentile of SOMDTP nodes for each compound. Panel B: histogram of the counts for these primary MOAs across SOM meta-clade groups. Primary MOAs appear color-coded in each vertical bar, with their heights corresponding to MOA counts in each meta-clade. Horizontal grayscale bar below Panel B indicates meta-clade groups A:G (reproduced from Fig 2 Panel A).